Sarah E S Leary

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7288568/publications.pdf

Version: 2024-02-01

57 papers	3,354 citations	304743 22 h-index	243625 44 g-index
58 all docs	58 docs citations	58 times ranked	4960 citing authors

#	Article	IF	Citations
1	Characteristics of patients â‰¥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-Oncology, 2022, 24, 141-152.	1.2	9
2	Phase II trial of response-based radiation therapy for patients with localized germinoma: a Childrenâ€™s Oncology Group study. Neuro-Oncology, 2022, 24, 974-983.	1.2	30
3	Two cases of pineal anlage tumor with molecular analysis. Pediatric Blood and Cancer, 2022, 69, e29596.	1.5	2
4	Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. Neuro-Oncology, 2022, , .	1.2	1
5	Mutations of the DNA repair gene PNKP in a patient with microcephaly, seizures, and developmental delay (MCSZ) presenting with a high-grade brain tumor. Scientific Reports, 2022, 12, 5386.	3.3	3
6	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). Neuro-Oncology, 2022, 24, 1178-1190.	1.2	13
7	SURG-12. Endoscopic evaluation of ventricular dissemination in primary central nervous system (CNS) germ cell tumors (GCTs). Neuro-Oncology, 2022, 24, i144-i144.	1.2	0
8	GCT-18. Endoscopic third ventriculostomy (ETV) and tumor biopsy are not associated with relapse rate or patterns in primary central nervous system (CNS) germ cell tumor (GCT). Neuro-Oncology, 2022, 24, i58-i58.	1.2	1
9	EPCT-05. Phase Ib study of unesbulin (PTC596) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): A report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). Neuro-Oncology, 2022, 24, i36-i36.	1.2	0
10	EPCT-06. Phase I study of ribociclib and everolimus post-radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): Updated report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). Neuro-Oncology, 2022, 24, i36-i37.	1.2	0
11	Molecularly Targeted Treatments for NF1-Mutant Diffuse Intrinsic Pontine Glioma. journal of applied laboratory medicine, The, 2021, 6, 550-553.	1.3	2
12	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTCâ€042). Pediatric Blood and Cancer, 2021, 68, e28879.	1.5	24
13	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
14	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
15	Predictors of mortality and tumor recurrence in desmoplastic infantile ganglioglioma and astrocytomaâ€”and individual participant data meta-analysis (IPDMA). Journal of Neuro-Oncology, 2021, 155, 155-163.	2.9	1
16	Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy. Pediatric Dermatology, 2021, 38, 18-30.	0.9	6
17	NIMG-11. VOLUMETRIC ENDPOINTS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): COMPARISON TO CROSS-SECTIONAL MEASURES AND CORRELATION WITH OUTCOMES. Neuro-Oncology, 2021, 23, vi129-vi130.	1.2	0
18	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell, 2020, 183, 1962-1985.e31.	28.9	177

#	Article	IF	Citations
19	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
20	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. Neuro-Oncology, 2020, 22, 1647-1657.	1.2	51
21	Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Childrenâ€™s Hospital experience. Journal of Neuro-Oncology, 2020, 148, 607-617.	2.9	21
22	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
23	A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific) Tj ETQq1 1 0.784314 rgBT /Overl		
24	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
25	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro-Oncology, 2019, 21, 968-980.	1.2	52
26	Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro-Oncology, 2019, 21, 83-94.	1.2	108
27	Unusual Radiographic Presentation of Intracranial Mature Teratoma and Resection via Supraorbital Approach. World Neurosurgery, 2019, 122, 81-84.	1.3	2
28	Gliomas in the context of Li-Fraumeni syndrome: An international cohort.. Journal of Clinical Oncology, 2019, 37, 1517-1517.	1.6	6
29	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 2018, 20, 1547-1555.	1.2	82
30	Year 1 in the Molecular Era of Pediatric Brain Tumor Diagnosis: Application of Universal Clinical Targeted Sequencing in an Unselected Cohort of Children. JCO Precision Oncology, 2018, 2, 1-13.	3.0	2
31	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250
32	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Childrenâ€™s Oncology Group Randomized ACNS0332 Trial. Journal of Clinical Oncology, 2018, 36, 3388-3395.	1.6	58
33	NSRG-15. FIRST IN HUMAN USE OF CANVAS IMAGING SYSTEM FOR VISUALIZATION OF TOZULERISTIDE-INDUCED TUMOR FLUORESCENCE. Neuro-Oncology, 2018, 20, i148-i148.	1.2	0
34	A phase 1/2 doseâ€finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatric Blood and Cancer, 2018, 65, e27217.	1.5	6
35	Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?. Pediatric Radiology, 2018, 48, 1472-1484.	2.0	19
36	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. Molecular Cancer Research, 2018, 16, 1491-1498.	3.4	39

#	Article	IF	Citations
37	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
38	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. Acta Neuropathologica Communications, 2018, 6, 67.	5.2	12
39	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600â€“mutant relapsed refractory low-grade glioma.. Journal of Clinical Oncology, 2018, 36, 10506-10506.	1.6	17
40	IMMU-11. BRAINCHILD PIPELINE: LOCOREGIONAL IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RECURRENT/REFRACTORY CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2018, 20, i100-i101.	1.2	0
41	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
42	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2017, 23, 6062-6069.	7.0	7
43	Description of a new oncogenic mechanism for atypical teratoid rhabdoid tumors in patients with ring chromosome 22. American Journal of Medical Genetics, Part A, 2017, 173, 245-249.	1.2	11
44	Preliminary exploratory data analysis of simulated national clinical data research network for future use in annotation of a rare tumor biobanking initiative. , 2017, , .		2
45	Survival After Relapse of Medulloblastoma. Journal of Pediatric Hematology/Oncology, 2016, 38, 269-273.	0.6	43
46	Phase II evaluation of sunitinib in the treatment of recurrent or refractory highâ€grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer Medicine, 2016, 5, 1416-1424.	2.8	53
47	NKG2D ligand expression in pediatric brain tumors. Cancer Biology and Therapy, 2016, 17, 1253-1265.	3.4	26
48	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
49	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. Journal of Clinical Oncology, 2015, 33, 2986-2998.	1.6	175
50	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	21.4	381
51	Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience. Cancer, 2013, 119, 2645-2653.	4.1	101
52	The molecular classification of medulloblastoma. Current Opinion in Pediatrics, 2012, 24, 33-39.	2.0	55
53	A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.. Journal of Clinical Oncology, 2012, 30, 9519-9519.	1.6	21
54	A phase I trial of MK 2206 in children with refractory solid tumors: A Childrenâ€™s Oncology Group study.. Journal of Clinical Oncology, 2012, 30, 9581-9581.	1.6	0

#	Article	IF	Citations
55	Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma. Cancer, 2011, 117, 3262-3267.	4.1	45
56	Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report. Neuro-Oncology Advances, 0, , .	0.7	3
57	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.7	6